Radius Plans to Test Cannabidiol RAD011 in Global Clinical Study

Radius Plans to Test Cannabidiol RAD011 in Global Clinical Study

301147

Radius Plans to Test Cannabidiol RAD011 in Global Clinical Study

Radius Health plans to initiate a Phase 2/3 study to evaluate the safety and efficacy of its investigational therapy RAD011, a lab-made oral cannabidiol therapy to treat excessive appetite, or hyperphagia, in people with Prader-Willi syndrome (PWS). The study, called SCOUT-015, is expected to begin by the end of this year or early in 2022, with top-line results anticipated in the second half of 2024. “We are encouraged by Radius’ commitment to advance RAD011 for…

You must be logged in to read/download the full post.